Skip to main content

Novel surface coating for biomedical devices


- To develop a new coating based on Titanium-Nitrid-Oxid as a low-adhesive surface material for reduced formation of bacterial-biofilm on biomaterials.

- To develop a new coating (TiNxOy) as low-thrombogenic surface material for the reduction of the clotting process on biomaterials.

- To test the anitthrombogenic potential of TiNxOy as a surface coating for prosthetic heart valves and to provide new data for the design of a novel artificial heart valve (no need for anticoagulation).

A novel surface coating has recently been developed which consists of a titanium-nitrid-oxid compound (TiNOx) and which is deposited by a physical vapour deposition process on biomaterials. This compound has a low surface adherence and electrophysical characteristics, which can be varied in a wide range between metallic and ceramic properties with a potential for a marked reduction in fibrinogen activation at the surface/blood interface. In a screening and evaluation phase the physico-chemical behaviour of different TiNOx coatings will be determined in respect of biofluid-adhesion, biofilm and thrombus formation. Various TiNOx films will be tested using static and dynamic methods i.e. contact angle measurements, continuos growth systems, shearforce and chemostat measurements for selected bacterial strains and a special designed flow chamber for investigation of fibrinogen and platelet activation. The influence of TiNOx-coating on the rheology of the mechanic heart valves will be investigated with Laser and MR - flow-models. On the basis of the results of these experiments the optimal TiNOx-coating will be selected for further in vivo testing. The performance of coated versus uncoated cardiac valves will be evaluated in the chronic pig-model with a follow-up for 3 to 6 months. A new monoclonal IgM platelet activation marker (developed by the laboratory for blood coagulation in Zurich) will be used to study platelet activation and thrombus formation in the animal model. This marker will be used for in vivo investigation of the activation of the coagulation system by coated and uncoated valves.

Funding Scheme

CSC - Cost-sharing contracts


Tinox - Gesellschaft für Energieforschung und Entwicklung mbH
80797 München

Participants (4)

Freeman Hospital
United Kingdom
Freeman Road High Heaton
NE7 7DN Newcastle Upon Tyne
Rijksuniversiteit Utrecht
3584 CX Utrecht
United Kingdom
University Walk
BS8 1TD Bristol, Clifton
Universität Zürich
8091 Zürich